Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Colorectal Cancer | Systematic Review

The role of piRNAs in predicting and prognosing in cancer: a focus on piRNA-823 (a systematic review and meta-analysis)

Authors: Mohammad Taghizadeh, Tohid Jafari-Koshki, Vahid Jafarlou, Mortaza Raeisi, Leila Alizadeh, Yousef Roosta, Somaieh Matin, Rahele Jabari, Daniel Sur, Abbas Karimi

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Introduction

This article examines the potential of using liquid biopsy with piRNAs to study cancer survival outcomes. While previous studies have explored the relationship between piRNA expression and cancer patient outcomes, a comprehensive investigation is still lacking. To address this gap, we conducted a systematic review and meta-analysis of existing literature.

Methods

We searched major online databases up to February 2024 to identify articles reporting on the role of piRNA in cancer patient survival outcomes. Our meta-analysis used a random-effects model to pool hazard ratios with 95% confidence intervals (CI) and assess the prognostic value of deregulated piRNA-823. For survival analysis, the Kaplan–Meier method and COX analysis were used.

Results

Out of 6104 articles screened, 20 met our inclusion criteria. Our analysis revealed that dysregulated piRNA expression is associated with cancer patient survival outcomes. Specifically, our meta-analysis found that overexpression of piR-823 is significantly linked with poorer overall survival in patients with colorectal cancer and renal cell cancer (HR: 3.82, 95% CI = [1.81, 8.04], I2 = 70%).

Conclusion

Our findings suggest that various piRNAs may play a role in cancer survival outcomes and that piRNA-823 in particular holds promise as a prognostic biomarker for multiple human cancers.

Implications for cancer survivors

Our systematic review and meta-analysis of piRNA-823 has important implications for cancer survivors. Our findings suggest that piRNA-823 can be used as a prognostic biomarker for predicting cancer recurrence and survival rates. This information can help clinicians develop personalized treatment plans for cancer survivors, which can improve their quality of life and reduce the risk of recurrence.
Literature
1.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed
2.
Wu X, Zhu L, Ma PC. Next-generation novel noninvasive cancer molecular diagnostics platforms beyond tissues. Am Soc Clin Oncol Educ Book. 2018;38:964–77.PubMedCrossRef
3.
De Silva F, Alcorn J. A tale of two cancers: A current concise overview of breast and prostate cancer. Cancers (Basel). 2022;14(12):2954.
4.
Crosby D, Bhatia S, Brindle KM, Coussens LM, Dive C, Emberton M, et al. Early detection of cancer. Science. 2022;375(6586):eaay9040.PubMedCrossRef
5.
Castro-Giner F, Gkountela S, Donato C, Alborelli I, Quagliata L, Ng CKY, et al. Cancer diagnosis using a liquid biopsy: challenges and expectations. Diagnostics (Basel). 2018;8(2)31.
6.
7.
8.
9.
Tanos R, Thierry AR. Clinical relevance of liquid biopsy for cancer screening. Vol. 7, Translational cancer research. AME Publishing Company; 2018. p. S105–29.
10.
Lone SN, Nisar S, Masoodi T, Singh M, Rizwan A, Hashem S, et al. Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments. Mol Cancer. 2022;21(1):79.PubMedPubMedCentralCrossRef
11.
Pantel K, Alix-Panabières C. Liquid biopsy: Potential and challenges. Mol Oncol. 2016;10(3):371–3.
12.
13.
Qu A, Wang W, Yang Y, Zhang X, Dong Y, Zheng G, et al. A serum piRNA signature as promising non-invasive diagnostic and prognostic biomarkers for colorectal cancer. Cancer Manag Res. 2019;11:3703–20.PubMedPubMedCentralCrossRef
14.
15.
Ghaseminezhad Z, Sharifi M, Bahreini A, Mehrzad V. Investigation of the expression of P-element-induced wimpy testis-interacting RNAs in human acute myeloid leukemia. Meta Gene. 2022;31:100998.CrossRef
16.
Zhou T. Chapter 3 - Small non-coding RNAs as epigenetic regulators. In: Ferguson BS, editor. Nutritional epigenomics. 14: Academic Press; 2019. p. 37–47.
17.
18.
Klattenhoff C, Theurkauf W. Biogenesis and germline functions of piRNAs. Development. 2008;135(1):3–9.PubMedCrossRef
19.
20.
Mokarram P, Niknam M, Sadeghdoust M, Aligolighasemabadi F, Siri M, Dastghaib S, et al. PIWI interacting RNAs perspectives: a new avenues in future cancer investigations. Bioengineered. 2021;12(2):10401–19.PubMedPubMedCentralCrossRef
21.
Hashim A, Rizzo F, Marchese G, Ravo M, Tarallo R, Nassa G, et al. RNA sequencing identifies specific PIWI-interacting small non-coding RNA expression patterns in breast cancer. Oncotarget. 2014;5(20):9901–10.
22.
Cheng Y, Wang Q, Jiang W, Bian Y, Zhou Y, Gou A, et al. Emerging roles of piRNAs in cancer: challenges and prospects. Aging (Albany NY). 2019;11(21):9932–46.PubMedCrossRef
23.
Weng W, Li H, Goel A. Piwi-interacting RNAs (piRNAs) and cancer: emerging biological concepts and potential clinical implications. Biochim Biophys Acta Rev Cancer. 2019;1871(1):160–9.PubMedCrossRef
24.
Mai D, Ding P, Tan L, Zhang J, Pan Z, Bai R, et al. PIWI-interacting RNA-54265 is oncogenic and a potential therapeutic target in colorectal adenocarcinoma. Theranostics. 2018;8(19):5213–30.PubMedPubMedCentralCrossRef
25.
Li D, Luo Y, Gao Y, Yang Y, Wang Y, Xu Y, et al. piR-651 promotes tumor formation in non-small cell lung carcinoma through the upregulation of cyclin D1 and CDK4. Int J Mol Med. 2016;38(3):927–36.PubMedCrossRef
26.
Iliev R, Fedorko M, Machackova T, Mlcochova H, Svoboda M, Pacik D, et al. Expression levels of PIWI-interacting RNA, piR-823, are deregulated in tumor tissue, blood serum and urine of patients with renal cell carcinoma. Anticancer Res. 2016;36(12):6419–23.PubMedCrossRef
27.
Feng J, Yang M, Wei Q, Song F, Zhang Y, Wang X, et al. Novel evidence for oncogenic piRNA-823 as a promising prognostic biomarker and a potential therapeutic target in colorectal cancer. J Cell Mol Med. 2020;24(16):9028–40.PubMedPubMedCentralCrossRef
28.
29.
Robinson AG, Booth CM, Eisenhauer EA. Disease-free survival as an end-point in the treatment of solid tumours – perspectives from clinical trials and clinical practice. Eur J Cancer. 2014;50(13):2298–302.PubMedCrossRef
30.
Rodriguez-Pascual J, Alvarez-Gallego R, Munoz C, Ugidos L, Sanz E, Ceniceros L, et al. Relapse-free survival (RFS) after surgical resection to predict survival after relapse (SAR) and overall survival (OS) in patients with pancreatic ductal adenocarcinoma (PDA). J Clin Oncol. 2019;37(15_suppl):e15735-e.CrossRef
31.
Anderton J, Moroz V, Marec-Bérard P, Gaspar N, Laurence V, Martín-Broto J, et al. International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours - EURO EWING 2012 Protocol. Trials. 2020;21(1):96.PubMedPubMedCentralCrossRef
32.
Yu Y, Carey M, Pollett W, Green J, Dicks E, Parfrey P, et al. The long-term survival characteristics of a cohort of colorectal cancer patients and baseline variables associated with survival outcomes with or without time-varying effects. BMC Med. 2019;17(1):150.PubMedPubMedCentralCrossRef
33.
Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815–34.PubMedCrossRef
34.
35.
Kärkkäinen E, Heikkinen S, Tengström M, Kosma VM, Mannermaa A, Hartikainen JM. The debatable presence of PIWI-interacting RNAs in invasive breast cancer. Cancer Med. 2021;10(11):3593–603.PubMedPubMedCentralCrossRef
36.
Li W, Gonzalez-Gonzalez M, Sanz-Criado L, Garcia-Carbonero N, Celdran A, Villarejo-Campos P, et al. A novel PiRNA enhances CA19–9 sensitivity for pancreatic cancer identification by liquid biopsy. J Clin Med. 2022;11(24):7310.
37.
Thorlund K, Imberger G, Johnston BC, Walsh M, Awad T, Thabane L, et al. Evolution of heterogeneity (I2) estimates and their 95% confidence intervals in large meta-analyses. PLoS ONE. 2012;7(7):e39471.PubMedPubMedCentralCrossRef
38.
39.
40.
Brüggemann P, Rajguru K. Comprehensive Meta-Analysis (CMA) 3.0: a software review. J Mark Anal. 2022;10(4):425–9.CrossRef
41.
Han H, Fan G, Song S, Jiang Y, Qian C, Zhang W, et al. piRNA-30473 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in DLBCL. Blood. 2021;137(12):1603–14.PubMedCrossRef
42.
Li G, Yi X, Du S, Gong L, Wu Q, Cai J, et al. Tumour-derived exosomal piR-25783 promotes omental metastasis of ovarian carcinoma by inducing the fibroblast to myofibroblast transition. Oncogene. 2023;42(6):421–33.PubMedCrossRef
43.
Ai L, Mu S, Sun C, Fan F, Yan H, Qin Y, et al. Myeloid-derived suppressor cells endow stem-like qualities to multiple myeloma cells by inducing piRNA-823 expression and DNMT3B activation. Mol Cancer. 2019;18(1):88.PubMedPubMedCentralCrossRef
44.
Busch J, Ralla B, Jung M, Wotschofsky Z, Trujillo-Arribas E, Schwabe P, et al. Piwi-interacting RNAs as novel prognostic markers in clear cell renal cell carcinomas. J Exp Clin Cancer Res. 2015;34(1):61.PubMedPubMedCentralCrossRef
45.
Bartos M, Siegl F, Kopkova A, Radova L, Oppelt J, Vecera M, et al. Small RNA sequencing identifies PIWI-interacting RNAs deregulated in Glioblastoma-piR-9491 and piR-12488 reduce tumor cell colonies in vitro. Front Oncol. 2021;11:707017.PubMedPubMedCentralCrossRef
46.
Zhou X, Liu J, Meng A, Zhang L, Wang M, Fan H, et al. Gastric juice piR-1245: a promising prognostic biomarker for gastric cancer. J Clin Lab Anal. 2020;34(4):e23131.PubMedCrossRef
47.
Martinez VD, Enfield KSS, Rowbotham DA, Lam WL. An atlas of gastric PIWI-interacting RNA transcriptomes and their utility for identifying signatures of gastric cancer recurrence. Gastric Cancer. 2016;19(2):660–5.PubMedCrossRef
48.
Krishnan AR, Korrapati A, Zou AE, Qu Y, Wang XQ, Califano JA, et al. Smoking status regulates a novel panel of PIWI-interacting RNAs in head and neck squamous cell carcinoma. Oral Oncol. 2017;65:68–75.PubMedCrossRef
49.
Saad MA, Ku J, Kuo SZ, Li PX, Zheng H, Yu MA, et al. Identification and characterization of dysregulated P-element induced wimpy testis-interacting RNAs in head and neck squamous cell carcinoma. Oncol Lett. 2019;17(3):2615–22.PubMedPubMedCentral
50.
Zhao C, Tolkach Y, Schmidt D, Toma M, Muders MH, Kristiansen G, et al. Mitochondrial PIWI-interacting RNAs are novel biomarkers for clear cell renal cell carcinoma. World J Urol. 2019;37(8):1639–47.PubMedCrossRef
51.
Krishnan P, Ghosh S, Graham K, Mackey JR, Kovalchuk O, Damaraju S. Piwi-interacting RNAs and PIWI genes as novel prognostic markers for breast cancer. Oncotarget. 2016;7(25):37944–56.PubMedPubMedCentralCrossRef
52.
Cordeiro A, Navarro A, Gaya A, Díaz-Beyá M, Gonzalez-Farré B, Castellano JJ, et al. PiwiRNA-651 as marker of treatment response and survival in classical Hodgkin lymphoma. Oncotarget. 2016;7(29):46002–13.PubMedPubMedCentralCrossRef
53.
Weng W, Liu N, Toiyama Y, Kusunoki M, Nagasaka T, Fujiwara T, et al. Novel evidence for a PIWI-interacting RNA (piRNA) as an oncogenic mediator of disease progression, and a potential prognostic biomarker in colorectal cancer. Mol Cancer. 2018;17(1):16.PubMedPubMedCentralCrossRef
54.
Firmino N, Martinez VD, Rowbotham DA, Enfield KSS, Bennewith KL, Lam WL. HPV status is associated with altered PIWI-interacting RNA expression pattern in head and neck cancer. Oral Oncol. 2016;55:43–8.PubMedPubMedCentralCrossRef
55.
Zhang W, Zheng Z, Wang K, Mao W, Li X, Wang G, et al. piRNA-1742 promotes renal cell carcinoma malignancy by regulating USP8 stability through binding to hnRNPU and thereby inhibiting MUC12 ubiquitination. Exp Mol Med. 2023;55(6):1258–71.PubMedPubMedCentralCrossRef
56.
Wang Y, Jiang X, Zhang D, Zhao Y, Han X, Zhu L, et al. LncRNA DUXAP8 as a prognostic biomarker for various cancers: a meta-analysis and bioinformatics analysis. Front Genet. 2022;13:907774.PubMedPubMedCentralCrossRef
57.
58.
59.
60.
Ameli Mojarad M, Ameli Mojarad M, Shojaee B, Nazemalhosseini-Mojarad E. piRNA: a promising biomarker in early detection of gastrointestinal cancer. Pathol Res Pract. 2022;230: 153757.PubMedCrossRef
61.
Hanusek K, Poletajew S, Kryst P, Piekiełko-Witkowska A, Bogusławska J. piRNAs and PIWI proteins as diagnostic and prognostic markers of genitourinary cancers. Biomolecules. 2022;12(2):186.PubMedPubMedCentralCrossRef
62.
Assumpção CB, Calcagno DQ, Araújo TMT, dos Santos Batista SE, dos Santos Ribeiro ÂKC, Riggins GJ, et al. The role of piRNA and its potential clinical implications in cancer. Epigenomics. 2015;7(6):975–84.PubMedCrossRef
63.
Vychytilova-Faltejskova P, Stitkovcova K, Radova L, Sachlova M, Kosarova Z, Slaba K, et al. Circulating PIWI-interacting RNAs piR-5937 and piR-28876 are promising diagnostic biomarkers of colon cancer. Cancer Epidemiol Biomarkers Prev. 2018;27(9):1019–28.PubMedCrossRef
Metadata
Title
The role of piRNAs in predicting and prognosing in cancer: a focus on piRNA-823 (a systematic review and meta-analysis)
Authors
Mohammad Taghizadeh
Tohid Jafari-Koshki
Vahid Jafarlou
Mortaza Raeisi
Leila Alizadeh
Yousef Roosta
Somaieh Matin
Rahele Jabari
Daniel Sur
Abbas Karimi
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-12180-2

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue

Research

Investigating the causal role of the gut microbiota in esophageal cancer and its subtypes: a two-sample Mendelian randomization study

Research

Exploring treatment outcomes in Stage II-III rectal cancer patients undergoing neoadjuvant therapy at a tertiary care center in Pakistan: a comprehensive analysis of pathological outcomes

Research

Tenascin C as a novel zinc finger protein 750 target regulating the immunogenicity via DNA damage in lung squamous cell carcinoma

Review

Diagnostic potential of exosomal extracellular vesicles in oncology

Study Protocol

A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi-centre, double-blind, placebo-controlled trial

Research

The prognostic role of single cell invasion and nuclear diameter in early oral tongue squamous cell carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits